Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
AC Immune SA (ACIU) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "​",
"​",
"​",
"​"
07/26/2023 6-K Quarterly results
05/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Invitation to the Annual General Meeting 2023 To the Shareholders of AC Immune SA",
"Consolidated Financial Statements (IFRS) as at and for the years ended December 31, 2022, 2021 and 2020 (incorporated by reference to Item 18 of Part III of AC Immune’ s Annual Report on Form 20-F for the fiscal year ended December 31, 2022 filed on March 16, 2023)"
04/28/2023 6-K Quarterly results
Docs: "6-K",
"Interim Condensed Consolidated Financial Statements (Unaudited) (IFRS) as of and for the three months ended March 31, 2023",
"Management’s Discussion and Analysis of Financial Condition and Results of Operations",
"AC Immune Reports First Quarter 2023 Financial Results",
"AC Immune SA"
03/16/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update",
"2022 Annual Report"
03/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
01/26/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"AC Immune’ s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’ s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial"
11/30/2022 6-K Quarterly results
10/28/2022 6-K Quarterly results
09/26/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer’ s Disease"
08/02/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Detailed data from the phase II Crenezumab Alzheimer’ s Prevention Initiative Study in Autosomal Dominant Alzheimer’ s Disease Presented at AAIC"
07/28/2022 6-K Quarterly results
06/24/2022 6-K Quarterly results
06/16/2022 6-K Quarterly results
05/25/2022 6-K Quarterly results
04/28/2022 6-K Quarterly results
Docs: "FORM 6-K",
"Interim Condensed Consolidated Financial Statements (Unaudited) (IFRS) as of and for the three months ended March 31, 2022",
"Management’ s Discussion and Analysis of Financial Condition and Results of Operations",
"AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update"
04/08/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Lausanne, Switzerland, April 8, 2022"
03/22/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update Seven clinical data readouts expected in 2022 Three vaccines, targeting Tau, Abeta and alpha-synuclein, advancing in 2022 Semorinemab Phase 2 Lauriet trial: additional fluid biomarker data expected in H2 2022 Initiation of ACI-24 anti-Abeta vaccine Phase 1b/2 trial in patients with Alzheimer’s disease and people living with Down syndrome expected in H1 2022 AD/PD™ Conference: ACI-12589 identified as a reliable and accurate PET tracer for alpha-synucleinopathies",
"2021 IFRS Consolidated Financial Statements",
"2021 Statutory Annual Report",
"2021 Compensation Report"
03/16/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PD TM Conference"
11/12/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"U.S. Media Shani Lewis LaVoieHealthScience Phone: +1 609 516 5761 Email: [email protected] U.S. Investors Corey Davis, Ph.D. LifeSci Advisors Phone: +1 212 915 2577 Email: [email protected] Forward looking statements"
11/08/2021 6-K Quarterly results
Docs: "FORM 6-K",
"Interim Condensed Consolidated Financial Statements (Unaudited) (IFRS) as of and for the three and nine months ended September 30, 2021",
"Management’ s Discussion and Analysis of Financial Condition and Results of Operations",
"AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate Update",
"Articles of Association as of October 21, 2021"
10/29/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors"
10/15/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
10/07/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Invitation to the Extraordinary General Meeting",
"2021 Extraordinary General Meeting Proxy Card"
08/31/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’ s Disease"
08/04/2021 6-K Quarterly results
Docs: "FORM 6-K",
"Asset Purchase and Contribution in Kind Agreement",
"Convertible Note Agreement with Santo Venture GmbH",
"Convertible Note Agreement with FCPB Affi GmbH",
"Interim Condensed Consolidated Financial Statements (Unaudited) (IFRS) as of and for the three and six months ended June 30, 2021",
"Management’ s Discussion and Analysis of Financial Condition and Results of Operations",
"AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update"
07/27/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"AC Immune Announces Strategic Acquisition of Industry-leading Parkinson’ s Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH"
06/25/2021 6-K Quarterly results
05/21/2021 6-K Quarterly results
05/05/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Open Market Sales Agreement, between AC Immune SA and Jefferies LLC",
"Opinion of Bär & Karrer Ltd"
04/28/2021 6-K Quarterly results
Docs: "FORM 6-K",
"Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the three months ended March 31, 2021",
"Management’ s Discussion and Analysis of Financial Condition and Results of Operations",
"AC Immune Reports First Quarter 2021 Financial Results and Provides Corporate Update"
03/31/2021 6-K Quarterly results
03/23/2021 6-K Quarterly results
02/26/2021 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy